The treatment started on the day following irradiation by administration of 12 mg/kg telmisartan
(Kushwaha & Jena, 2013) (commercial product--Micardis[R]), one time per day and 34 mg/kg losartan (Kharofa et al.
015) in pioglitazone treated group, while telmisartan
only managed to convert a negative correlation between insulin and glucose into statistically non-significant positive.
This study dealt with the comparative study of telmisartan
and ramipril as an antihypertensive in mild to moderate hypertension.
Therefore, in a multicenter, prospective, double-dummy randomized clinical trial (RCT), we evaluated the efficacy and safety of the angiotensin receptor blocker (ARB) telmisartan
in combination with the antiplatelet drug clopidogrel, the immunosuppressant leflunomide, or both drugs for managing IgAN.
In earlier research, the same team found that telmisartan
and another hypertension drug, candesartan, had beneficial effects in mice with traumatic brain injury several hours after injury.
The patients were randomly allocated to receive either telmisartan
or lisinopril with 30 patients in each group.
All patients were treated with telmisartan
at the dose of 80 mg administered orally once a day and were controlled every 6 month for 3 years.
All the odd study numbers were allotted to ramipril group and even study numbers to telmisartan
The company added that the Telmisartan
Tablets USP, 20 mg, 40 mg and 80 mg are the generic version of Boehringer Ingelheim's Micardis Tablets.
Soz konusu ARB'ler ise losartan, candesartan, telmisartan
ve valsartan olmaktadir.
TWYNSTAEeA is indicated for the treatment of hypertension in adults whose blood pressure is not adequately controlled on amlodipine or as replacement therapy in adult patients receiving telmisartan
and amlodipine from separate tablets containing the same component doses.
Until regulators review the possible association between ARB use and cancer and report their findings, we should use ARBs, particularly telmisartan
, with greater caution.
However, dual blockade has come into disrepute after the recent Ongoing Telmisartan
Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) trial (10) which has shown that dual blockade is more efficacious in BP reduction compared to single agent, but dual blockade was associated with more renal dysfunction with some requiring haemodialysis.
Most of the data in the analysis was drawn from studies of telmisartan
, which is marketed as Micardis, among other names.
More than 85% of the patients were taking one type of ARB, telmisartan